Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharma Goes 3 For 3 In Presidential Debates

Executive Summary

The Presidential debates are over, and the biopharmaceutical industry has to be counted among the winners, simply because there was no substantive discussion of high drug prices as an issue. That may not mean much come 2017 – but at least the industry’s reputation hasn’t been further damaged during the highest profile phase of the national campaign.

You may also be interested in...

Clinton Transition Co-Chair Tanden Offers Themes For A Drug Pricing Bill In 2017

FAIR Drug Pricing Act, CAP proposal and Collins bill include viable legislative movers for next administration. CMS Acting Administrator Slavitt signals that Part B demo will move forward based on CBO score.

Drug Prices Enter Presidential Debate – Not That Anyone Noticed

Second Presidential debate included the first direct discussion of health care issues by the candidates, and the first reference to prescription drug costs. The passing reference was, to put it mildly, overshadowed by other topics.

Big Pharma’s Big Debate Win

Sometimes silence is golden. The first Presidential debate had lots of noise – but no discussion of health care, much less drug pricing. And, as an added bonus, both candidates agreed that tax repatriation is a good idea.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts